quote:Originally posted by stocktrader2006: Sally,
My replies to you will be left un-said to you in this public forum - mostly because I respect women, and I will not want to insult you if need be, in a public forum...if you have a beef with me, PM me. Thank you, and I look forward to hearing from you.
Keep looking.
Why would I subject myself to an obvious insult in private? Honestly, it's not the first time I've ever been insulted so say what you need to say. If you weren't addressing me with the "newbie traders/experts" comment, that's cool. And I did PUBLICLY apologize for the "nitwit" comment without even being asked for an apology.
quote:Originally posted by stocktrader2006: Sally,
My replies to you will be left un-said to you in this public forum - mostly because I respect women, and I will not want to insult you if need be, in a public forum...if you have a beef with me, PM me. Thank you, and I look forward to hearing from you.
Keep looking.
Why would I subject myself to an obvious insult in private? Honestly, it's not the first time I've ever been insulted so say what you need to say. If you weren't addressing me with the "newbie traders/experts" comment, that's cool. And I did PUBLICLY apologize for the "nitwit" comment without even being asked for an apology.
Don't worry about it , he just got mad cause he is a BAG HOLDER somewhere no reason to be shame STOCK we all got burned in this game ,LOOK AT ME
i am a proud to be a BAG HOLDER here LOL Posts: 4112 | Registered: Jun 2006
| IP: Logged |
quote:Originally posted by stocktrader2006: Sally,
My replies to you will be left un-said to you in this public forum - mostly because I respect women, and I will not want to insult you if need be, in a public forum...if you have a beef with me, PM me. Thank you, and I look forward to hearing from you.
Keep looking.
Why would I subject myself to an obvious insult in private? Honestly, it's not the first time I've ever been insulted so say what you need to say. If you weren't addressing me with the "newbie traders/experts" comment, that's cool. And I did PUBLICLY apologize for the "nitwit" comment without even being asked for an apology.
Guess I have all you stocktrader992587516548's confused? (FGFC thread altercation) Oops.
posted
Folks like I said I have pulled certs so I don't make the mistake of selling now. I have some that I play with but to me this has always been a long hold.
Now Col. Pandey I like to call him that because he was one. is coming back to New Jersey next week and I think we will get some solid news to.
I think this may start to base again at three next week this is just my opinion.
I have been in this when I never thought it would get off of .01. And actually the company is more solid now than it ever was. Looks like it will make itand Pandey should be ceo of the year just for hanging on.
hope all of you read my Sept 2003 pr that I posted telling of the phase 2 clinicals,orphan drug statis, and a very brief comment on drugs in the pipeline.
If you did read it you know this is real and we have a chance to be in at 2 cents in two years just think of what you will have. So bash away anybody that wants to if this runs I will play it but my core investment is tucked away not to be touched. That is for my granddaughter.
Posts: 6008 | From: phoenix az | Registered: Mar 2005
| IP: Logged |
posted
I'm still following the trench Bond. Good luck. gonna take a while..............IMO of course
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Hehe Dollar, up 9% today, down 14 tomorrow. Seems like how it goes with this thing lately Posts: 723 | From: MotorCity | Registered: Jun 2006
| IP: Logged |
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
Source: Virginia Commonwealth University Released: Tue 07-Nov-2006, 16:55 ET Printer-friendly Version
Researchers Develop Novel Method for Treatment of Sickle Cell Disease Libraries Medical News Keywords SICKLE CELL, SICKLE CELL DISEASE, SICKLE CELL TREATMENT, PATENT Contact Information
Available for logged-in reporters only Description
Virginia Commonwealth University researchers have developed a unique anti-sickling agent that may one day be effective in treating sickle cell disease, a painful and debilitating genetic blood disorder that affects approximately 80,000 Americans.
Newswise =E2=80=94 Virginia Commonwealth University researchers have developed a unique anti-sickling agent that may one day be effective in treating sickle cell disease, a painful and debilitating genetic blood disorder that affects approximately 80,000 Americans.
The research team led by Donald Abraham, Ph.D., of Biological and Medicinal Chemistry, in the Department of Medicinal Chemistry in VCU=E2=80=99s School of Pharmacy, has shown that 5-HMF, a pure compound developed by the team, has a high affinity for sickle cell hemoglobin and holds promise for the treatment of sickle cell disease.
=E2=80=9COur findings suggest that this anti-sickling agent may lead to new drug treatments and may one day help those suffering with sickle cell disease. This molecule, 5-HMF, is the most promising molecule to treat sickle cell anemia to come from our research group in more than 30 years,=E2=80=9D said Abraham, who is also the director of the Institute of Structural Biology and Drug Discovery.
The United States Patent and Trademark Office recently issued VCU a Notice of Allowance for a patent relating to a method of treating sickle cell disease with 5-HMF compound. A Notice of Allowance is a written notification that a patent application has cleared an internal review and it has been approved for issuance.
Sickle cell disease is caused by an abnormality in the hemoglobin molecule. Normal red blood cells carrying hemoglobin are smooth, round and flexible and can travel easily throughout blood vessels. However, sickle cells are stiff, abnormally shaped, red blood cells that do not flow freely through blood vessels. The sickle cells also may clot together causing a blockage to form which results in pain and potentially dangerous complications that can compromise a patient=E2=80=99s organs.
According to Abraham, the 5-membered, heterocyclic, anti-sickling agent binds to hemoglobin to increase the oxygen affinity of both normal and sickle hemoglobin. In a patient with sickle cell disease, the binding action of 5-HMF would allow sickle cells to move more smoothly throughout the blood vessels of the body and prevent blockages from forming.
Abraham is internationally known for his groundbreaking work discovering and developing drugs that interact with hemoglobin. His research focus is to develop targeted therapeutics in sickle cell anemia, cardiovascular disease, stroke, cancer, Alzheimer=E2=80=99s disease and radiation oncology.
This research was supported in part by a grant from the National Institutes of Health.
Xechem International, Inc., a biopharmaceutical company headquartered in New Brunswick, N.J., has entered into a licensing agreement with VCU Technology Transfer and has the exclusive worldwide rights for the production, sales and marketing of 5-HMF for use to fight sickle cell disease.
A recent grant from the National Heart, Lung and Blood Institute, part of the National Institutes of Health, awarded to Xechem International Inc., will allow researchers to carry out toxicity studies on 5-HMF. The research team will include researchers from VCU and Children=E2=80=99s Hospital of Philadelphia, University of Philadelphia.
Working with Abraham to develop the anti-sickling agent were: Martin K. Safo, Ph.D., Richmond Danso-Danquah, Ph.D., and Gajanan S. Joshi, Ph.D., all researchers in the VCU Department of Medicinal Chemistry.
About VCU and the VCU Medical Center: Virginia Commonwealth University is the largest university in Virginia and ranks among the top 100 universities in the country in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 30,000 students in nearly 200 certificate and degree programs in the arts, sciences and humanities. Sixty-three of the programs are unique in Virginia, many of them crossing the disciplines of VCU=E2=80=99s 15 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation=E2=80=99s leading academic medical centers. For more, see http://www.vcu.edu.
About Xechem: Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem=E2=80=99s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN=E2=84=A2 (named HEMOXIN=E2=84=A2 in the US and Europe) for the prophylactic manageme= nt of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN=E2=84=A2, Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval.
Video available by contacting the source
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
NEW YORK, Nov 29, 2006 (BUSINESS WIRE) -- The New York Society of Security Analysts (NYSSA) will present the 10th Annual Biotech/Specialty Pharma Conference on December 12 to 13, 2006.
What does the future have in store for the biotech industry? Don't miss this chance to hear Michael D. West, PhD, president of Advanced Cell Technology and author of The Immortal Cell: One Scientist's Quest to Solve the Mystery of Human Aging, discuss the emerging field of stem cell research. Other presentations include companies focused on hormone therapy, drug delivery and treatments for HIV/AIDS and cancer.
The following companies are presenting on day one:
Aradigm Corporation (ARDM, Trade ); BioSante Pharmaceuticals, Inc. (BPA, Trade ); CytRx Corporation (CYTR, Trade ); DNAPrint Genomics, Inc. (DNAG, Trade ); DRAXIS Health Inc. (DRAX, Trade ); DURECT Corporation (DRRX, Trade ); Heska Corporation (HSKA, Trade ); The Immune Response Corporation (IMNR, Trade ); Viral Genetics, Inc. (VRAL, Trade ); and Xechem International, Inc. (XKEM, Trade ).
The following companies are presenting on day two:
Advanced Cell Technology, Inc. (ACTC, Trade ); Cleveland BioLabs, Inc. (CBLI, Trade ); Cyclacel Pharmaceuticals, Inc. (CYCC, Trade ); EntreMed, Inc. (ENMD, Trade ); Neuro-Hitech Pharmaceuticals, Inc. (NHPI, Trade ); Provectus Pharmaceuticals, Inc. (PVCT, Trade ); The Quigley Corporation (QGLY, Trade ); and XTL Biopharmaceuticals Ltd. (XTLB, Trade ).
The conference will be held on December 12, 2006, 8:30 a.m. to 5:10 p.m., and December 13, 2006, 8:30 a.m. to 4:30 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, NYC. Registration deadline is December 5, one day, $265 NYSSA members, $365 nonmembers; two days, $365 NYSSA members, $465 nonmembers. No charge for press with credentials. A complete agenda is available at
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
About NYSSA
NYSSA, established in 1937, is the premier independent forum for the exchange of information among investment decision-makers. A not-for-profit educational organization with over 9,500 members, NYSSA is committed to the promotion of best practices and the highest professional and ethical standards in the investment industry. NYSSA is the largest of the more than 134 societies worldwide that make up CFA Institute, which has more than 83,000 members.
SOURCE: The New York Society of Security Analysts
The New York Society of Security Analysts Dawn Cavalieri, 212-541-4530, ext. 20 press*nyssa.org
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
12/12 is my birthday. I wish for over 3 cents for my birthday present. Birthday wishes have to come true, especially if Pandy is speaking that day. Let's home he's takin a public speaking lesson since Dallas.
Posts: 551 | From: FL | Registered: Apr 2006
| IP: Logged |
quote:Originally posted by GreenDay: 12/12 is my birthday. I wish for over 3 cents for my birthday present. Birthday wishes have to come true, especially if Pandy is speaking that day. Let's home he's takin a public speaking lesson since Dallas.
LMAO!!!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
I just thought out loud that if they plan on having 200-300 Mill in sales the next few years, I thought that would mean prolly .25-.50 cents a share, maybe?
That would be nice, but could be wishful thinking too. Not in a rush to sell, but would like to make some cash on this
Red
Posts: 723 | From: MotorCity | Registered: Jun 2006
| IP: Logged |
posted
Ya it seems to have bottomed out. I am not ashamed to say I have buying points at .013, .03, and at .07. So yes I am Red some, but I think it would be worth at least a dime in the next 6 months.
Maybe not, but they got things setup for the long haul, just not to keen on those extra shares out there now
Red
Posts: 723 | From: MotorCity | Registered: Jun 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
no reason to be shame STOCK we all got burned in this game ,LOOK AT ME ![[Razz]](tongue.gif)
![[Smile]](smile.gif)
![[Eek!]](eek.gif)
![[Frown]](frown.gif)
